Skip to main content
SpringerLink
Log in

Extent of Resection and Outcomes of Patients with Primary Malignant Brain Tumors

  • Published:
Current Treatment Options in Oncology Aims and scope Submit manuscript

Opinion statement

We have level II evidence that attempting a gross total resection of newly diagnosed suspected glioblastoma is preferred when a maximally safe resection can be attempted. This recommendation extends to elderly patients and those with butterfly gliomas. However, in cases where patients are poor surgical candidates, or for lesions in eloquent areas, subtotal resection or biopsy may be indicated. Recent studies have discussed “supramaximal surgery,” which is defined in different ways by different teams, but there is not enough evidence, yet, to make a consistent recommendation for supramaximal resection for specific patients.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Subscribe and save

Springer+ Basic
$34.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or eBook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. Grochans S, Cybulska AM, Simińska D, Korbecki J, Kojder K, Chlubek D, Baranowska-Bosiacka I. Epidemiology of glioblastoma multiforme-literature review. Cancers. 2022;14(10):2412. https://doi.org/10.3390/cancers14102412.

    Article  PubMed  PubMed Central  Google Scholar 

  2. Iturrioz-Rodríguez N, De Pasquale D, Fiaschi P, Ciofani G. Discrimination of glioma patient-derived cells from healthy astrocytes by exploiting Raman spectroscopy. Spectrochim Acta A Mol Biomol Spectrosc. 2022;269:120773. https://doi.org/10.1016/j.saa.2021.120773.

  3. Ohgaki H, Kleihues P. The definition of primary and secondary glioblastoma. Clin Cancer Res. 2013;19(4):764–72. https://doi.org/10.1158/1078-0432.CCR-12-3002.

    Article  CAS  PubMed  Google Scholar 

  4. Jusue-Torres I, Prabhu VC, Jones GA. Dandy’s hemispherectomies: historical vignette. J Neurosurg. 2021;135(6):1836–42. https://doi.org/10.3171/2020.9.JNS202824.

    Article  PubMed  Google Scholar 

  5. Lara-Velazquez M, Al-Kharboosh R, Jeanneret S, Vazquez-Ramos C, Mahato D, Tavanaiepour D, Rahmathulla G, Quinones-Hinojosa A. Advances in brain tumor surgery for glioblastoma in adults. Brain Sci. 2017;7(12):166. https://doi.org/10.3390/brainsci7120166.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Seker-Polat F, Pinarbasi Degirmenci N, Solaroglu I, Bagci-Onder T. Tumor cell infiltration into the brain in glioblastoma: from mechanisms to clinical perspectives. Cancers (Basel). 2022;14(2):443. https://doi.org/10.3390/cancers14020443.

    Article  CAS  PubMed  Google Scholar 

  7. Kondziolka D, Dade Lunsford L. The role of stereotactic biopsy in the management of gliomas. J Neurooncol. 1999;42:205–13. https://doi.org/10.1023/A:1006105415194.

    Article  CAS  PubMed  Google Scholar 

  8. Lacroix M, Abi-Said D, Fourney DR, Gokaslan ZL, Shi W, DeMonte F, Lang FF, McCutcheon IE, Hassenbusch SJ, Holland E, Hess K, Michael C, Miller D, Sawaya R. A multivariate analysis of 416 patients with glioblastoma multiforme: prognosis, extent of resection, and survival. J Neurosurg. 2001;95(2):190–8. https://doi.org/10.3171/jns.2001.95.2.0190.

    Article  CAS  PubMed  Google Scholar 

  9. Stummer W, Pichlmeier U, Meinel T, Wiestler OD, Zanella F, Reulen HJ, ALA-Glioma Study Group. Fluorescence-guided surgery with 5-aminolevulinic acid for resection of malignant glioma: a randomised controlled multicentre phase III trial. Lancet Oncol. 2006;7(5):392–401. https://doi.org/10.1016/S1470-2045(06)70665-9.

    Article  CAS  PubMed  Google Scholar 

  10. Sanai N, Polley MY, McDermott MW, Parsa AT, Berger MS. An extent of resection threshold for newly diagnosed glioblastomas. J Neurosurg. 2011;115(1):3–8. https://doi.org/10.3171/2011.2.jns10998.

    Article  PubMed  Google Scholar 

  11. Kreth FW, Thon N, Simon M, Westphal M, Schackert G, Nikkhah G, Hentschel B, Reifenberger G, Pietsch T, Weller M, Tonn JC, German Glioma N. Gross total but not incomplete resection of glioblastoma prolongs survival in the era of radiochemotherapy. Ann Oncol. 2013;24:3117–23. https://doi.org/10.1093/annonc/mdt38.

    Article  PubMed  Google Scholar 

  12. Noorbakhsh A, Tang JA, Marcus LP, McCutcheon B, Gonda DD, Schallhorn CS, Talamini MA, Chang DC, Carter BS, Chen CC. Gross-total resection outcomes in an elderly population with glioblastoma: a SEER-based analysis. J Neurosurg. 2014;120(1):31–9. https://doi.org/10.3171/2013.9.JNS13877.

    Article  PubMed  Google Scholar 

  13. Awad AW, Karsy M, Sanai N, et al. Impact of removed tumor volume and location on patient outcome in glioblastoma. J Neurooncol. 2017;135:161–71. https://doi.org/10.1007/s11060-017-2562-1.

    Article  PubMed  Google Scholar 

  14. Cui M, Chen H, Sun G, et al. Combined use of multimodal techniques for the resection of glioblastoma involving corpus callosum. Acta Neurochir. 2022;164:689–702. https://doi.org/10.1007/s00701-021-05008-6.

    Article  PubMed  Google Scholar 

  15. Mohammed S, Dinesan M, Ajayakumar T. Survival and quality of life analysis in glioblastoma multiforme with adjuvant chemoradiotherapy: a retrospective study. Rep Pract Oncol Radiother. 2022;27(6):1026–36. https://doi.org/10.5603/RPOR.a2022.0113.

    Article  PubMed  PubMed Central  Google Scholar 

  16. Vivas-Buitrago T, Domingo RA, Tripathi S, De Biase G, Brown D, Akinduro OO, Ramos-Fresnedo A, Sabsevitz DS, Bendok BR, Sherman W, Parney IF, Jentoft ME, Middlebrooks EH, Meyer FB, Chaichana KL, Quinones-Hinojosa A. Influence of supramarginal resection on survival outcomes after gross-total resection of IDH-wild-type glioblastoma. J Neurosurg. 2021;136(1):1–8. https://doi.org/10.3171/2020.10.JNS203366. The study reported improvement in OS after supramarginal resection regardless of age. A key study since age is one of the many factors that influence survival in GBM resection.

    Article  PubMed  PubMed Central  Google Scholar 

  17. Pessina F, Navarria P, Cozzi L, Ascolese AM, Simonelli M, Santoro A, Clerici E, Rossi M, Scorsetti M, Bello L. Maximize surgical resection beyond contrast-enhancing boundaries in newly diagnosed glioblastoma multiforme: is it useful and safe? A single institution retrospective experience. J Neuro-Oncol. 2017;135:129–39.

    Article  Google Scholar 

  18. Shah AH, Mahavadi A, Di L, et al. Survival benefit of lobectomy for glioblastoma: moving towards radical supramaximal resection. J Neurooncol. 2020;148:501–8. https://doi.org/10.1007/s11060-020-03541-5\.

    Article  PubMed  PubMed Central  Google Scholar 

  19. Khalafallah AM, Rakovec M, Bettegowda C, Jackson CM, Gallia GL, Weingart JD, Lim M, Esquenazi Y, Zacharia BE, Goldschmidt E, Ziu M, Ivan ME, Venteicher AS, Nduom EK, Mamelak AN, Chu RM, Yu JS, Sheehan JP, Nahed BV, Carter BS, Berger MS, Sawaya R, Mukherjee D. A crowdsourced consensus on supratotal resection versus gross total resection for anatomically distinct primary glioblastoma. Neurosurgery. 2021;89(4):712–9. https://doi.org/10.1093/neuros/nyab257. The study surveyed neurosurgeons to identify the understanding of the definition of supramaximal resection. Currently, there has been no consensus on supramarginal vs supramaximal, and this paper surveyed the current landscape.

    Article  PubMed  PubMed Central  Google Scholar 

  20. Molinaro AM, Hervey-Jumper S, Morshed RA, et al. Association of maximal extent of resection of contrast-enhanced and non-contrast-enhanced tumor with survival within molecular subgroups of patients with newly diagnosed glioblastoma [published correction appears in JAMA Oncol. 2020 Mar 1;6(3):444]. JAMA Oncol. 2020;6(4):495–503. https://doi.org/10.1001/jamaoncol.2019.6143. Compared maximal EOR of CE tumors across different age groups and found a difference in survival between younger and older populations.

    Article  PubMed  PubMed Central  Google Scholar 

  21. Tripathi S, Vivas-Buitrago T, Domingo RA, Biase G, Brown D, Akinduro OO, Ramos-Fresnedo A, Sherman W, Gupta V, Middlebrooks EH, Sabsevitz DS, Porter AB, Uhm JH, Bendok BR, Parney I, Meyer FB, Chaichana KL, Swanson KR, Quiñones-Hinojosa A. IDH-wild-type glioblastoma cell density and infiltration distribution influence on supramarginal resection and its impact on overall survival: a mathematical model. J Neurosurg. 2021;136(6):1567–75. https://doi.org/10.3171/2021.6.JNS21925. Investigated the efficacy of supramarginal resection depending on tumor differences and found a difference in survival when comparing nodular tumors vs moderately diffuse vs highly diffuse tumors.

    Article  PubMed  PubMed Central  Google Scholar 

  22. Baldock AL, Ahn S, Rockne R, Johnston S, Neal M, Corwin D, Clark-Swanson K, Sterin G, Trister AD, Malone H, Ebiana V, Sonabend AM, Mrugala M, Rockhill JK, Silbergeld DL, Lai A, Cloughesy T, McKhann GM 2nd, Bruce JN, Rostomily RC, Canoll P, Swanson KR. Patient-specific metrics of invasiveness reveal significant prognostic benefit of resection in a predictable subset of gliomas. PLoS ONE. 2014;9(10):e99057. https://doi.org/10.1371/journal.pone.0099057.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  23. Cui M, Chen H, Sun G, et al. Combined use of multimodal techniques for the resection of glioblastoma involving corpus callosum. Acta Neurochir. 2022;164:689–702. https://doi.org/10.1007/s00701-021-05008-6.

    Article  PubMed  Google Scholar 

  24. Altieri R, Certo F, Pacella D, et al. Metabolic delineation of IDH1 wild-type glioblastoma surgical anatomy: how to plan the tumor extent of resection. J Neurooncol. 2023;162:417–23. https://doi.org/10.1007/s11060-023-04305-7. Utilized 11[C]-MET-PET to evaluate metabolic activity of tumor beyond FLAIR imaging, which showed the invasive nature of GBM tumor cells.

    Article  CAS  PubMed  Google Scholar 

  25. Otsuji R, Hata N, Funakoshi Y, Kuga D, Togao O, Hatae R, Sangatsuda Y, Fujioka Y, Takigawa K, Sako A, Kikuchi K, Yoshitake T, Yamamoto H, Mizoguchi M, Yoshimoto K. Supramaximal resection can prolong the survival of patients with cortical glioblastoma: a volumetric study. Neurol Med Chir (Tokyo). 2023;63(8):364–374. https://doi.org/10.2176/jns-nmc.2022-0351. Provided a cutoff for supramaximal resection (30% beyond CE), but highlighted differences in OS depending on tumor location.

  26. Karschnia P, Young JS, Dono A, Häni L, Sciortino T, Bruno F, Juenger ST, Teske N, Morshed RA, Haddad AF, Zhang Y, Stoecklein S, Weller M, Vogelbaum MA, Beck J, Tandon N, Hervey-Jumper S, Molinaro AM, Rudà R, Bello L, Schnell O, Esquenazi Y, Ruge MI, Grau SJ, Berger MS, Chang SM, van den Bent M, Tonn JC. Prognostic validation of a new classification system for extent of resection in glioblastoma: a report of the RANO resect group. Neuro Oncol. 2023;25(5):940–54. https://doi.org/10.1093/neuonc/noac193. One of the largest recent retrospective studies that aimed to provide a clear definition of supramaximal resection to avoid ambiguity.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Emory University School of Medicine, Atlanta, GA, USA

    Brandy Ndirangu MS

  2. Morehouse School of Medicine, Atlanta, GA, USA

    Kevon Bryan MS

  3. Emory Winship Cancer Institute, 1365 Clifton Rd NE, Atlanta, GA, C5084 30322, USA

    Edjah Nduom MD

Authors
  1. Brandy Ndirangu MS
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Kevon Bryan MS
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Edjah Nduom MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Edjah Nduom MD.

Ethics declarations

Data Availability

The data used to support the findings in this study are openly available https://www.ncbi.nlm.nih.gov.

Author Contributions

Brandy Ndirangu contributed greatly to this work. All authors reviewed the manuscript.

Conflict of Interest

The authors declare no competing interests.

Human and Animal Rights and Informed Consent

This article does not contain any human or animal subjects performed by any of the authors.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Ndirangu, B., Bryan, K. & Nduom, E. Extent of Resection and Outcomes of Patients with Primary Malignant Brain Tumors. Curr. Treat. Options in Oncol. 24, 1948–1961 (2023). https://doi.org/10.1007/s11864-023-01158-0

Download citation

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11864-023-01158-0

Keywords

Search

Navigation